Transforaminal lumbar epidural injection of dexmedetomidine versus magnesium sulfate combined with dexamethasone for lower limb radicular pain management: a randomized, clinical trial.

Mina Maher Raouf, Gehan Ibrahim Abdelrazek Salem, Fady Adib Abdel Malek, Tamer Youssef Elie Hamawy, Sadik Abdel-Maseeh Sadik, Mohammad Awad Elsaed
{"title":"Transforaminal lumbar epidural injection of dexmedetomidine versus magnesium sulfate combined with dexamethasone for lower limb radicular pain management: a randomized, clinical trial.","authors":"Mina Maher Raouf, Gehan Ibrahim Abdelrazek Salem, Fady Adib Abdel Malek, Tamer Youssef Elie Hamawy, Sadik Abdel-Maseeh Sadik, Mohammad Awad Elsaed","doi":"10.17085/apm.24125","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epidural steroid injections are frequently used to treat chronic radicular pain of a discogenic origin; however, their efficacy remains limited. Magnesium sulfate and dexmedetomidine are emerging adjuvants with the potential to enhance the effectiveness and prolong the therapeutic duration of steroid injections.</p><p><strong>Methods: </strong>In this randomized, double-blind study, 90 patients with unilateral lower limb radiculopathy due to lumbar disc prolapse who did not respond to conservative treatment for 12 weeks were assigned to three groups. The control group received dexamethasone (4 mg), lidocaine 2% (40 mg), and saline. The magnesium group received magnesium sulfate (200 mg) with dexamethasone and lidocaine. The dexmedetomidine group received dexmedetomidine (50 mcg), dexamethasone, lidocaine, and saline. Pain intensity was assessed using the visual analog scale at 1 week and 1, 3, and 6 months post-treatment. Secondary outcomes included the Modified Oswestry Disability Index (MODI), analgesic consumption, and procedure-related complications.</p><p><strong>Results: </strong>Both magnesium and dexmedetomidine significantly reduced pain, disability, and analgesic consumption for up to 3 months. By 6 months, the magnesium group demonstrated significant improvement in pain scores and MODI and a decline in ibuprofen use compared to the control and dexmedetomidine groups.</p><p><strong>Conclusions: </strong>Magnesium significantly reduced pain intensity, disability, and analgesic consumption over a 6-month observation period.</p>","PeriodicalId":101360,"journal":{"name":"Anesthesia and pain medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesia and pain medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17085/apm.24125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Epidural steroid injections are frequently used to treat chronic radicular pain of a discogenic origin; however, their efficacy remains limited. Magnesium sulfate and dexmedetomidine are emerging adjuvants with the potential to enhance the effectiveness and prolong the therapeutic duration of steroid injections.

Methods: In this randomized, double-blind study, 90 patients with unilateral lower limb radiculopathy due to lumbar disc prolapse who did not respond to conservative treatment for 12 weeks were assigned to three groups. The control group received dexamethasone (4 mg), lidocaine 2% (40 mg), and saline. The magnesium group received magnesium sulfate (200 mg) with dexamethasone and lidocaine. The dexmedetomidine group received dexmedetomidine (50 mcg), dexamethasone, lidocaine, and saline. Pain intensity was assessed using the visual analog scale at 1 week and 1, 3, and 6 months post-treatment. Secondary outcomes included the Modified Oswestry Disability Index (MODI), analgesic consumption, and procedure-related complications.

Results: Both magnesium and dexmedetomidine significantly reduced pain, disability, and analgesic consumption for up to 3 months. By 6 months, the magnesium group demonstrated significant improvement in pain scores and MODI and a decline in ibuprofen use compared to the control and dexmedetomidine groups.

Conclusions: Magnesium significantly reduced pain intensity, disability, and analgesic consumption over a 6-month observation period.

经椎间孔腰椎硬膜外注射右美托咪定与硫酸镁联合地塞米松治疗下肢神经根性疼痛:一项随机临床试验
背景:硬膜外类固醇注射常用于治疗椎间盘源性慢性根性疼痛,但其疗效仍然有限。硫酸镁和右美托咪定是新兴的辅助药物,有可能提高类固醇注射的疗效并延长治疗时间:在这项随机双盲研究中,90名因腰椎间盘突出症而导致单侧下肢根性病变、保守治疗12周无效的患者被分为三组。对照组接受地塞米松(4 毫克)、2% 利多卡因(40 毫克)和生理盐水治疗。镁组接受硫酸镁(200 毫克)、地塞米松和利多卡因。右美托咪定组使用右美托咪定(50 微克)、地塞米松、利多卡因和生理盐水。使用视觉模拟量表评估治疗后 1 周、1、3 和 6 个月的疼痛强度。次要结果包括改良奥斯韦特里残疾指数(MODI)、镇痛药消耗量和手术相关并发症:结果:镁和右美托咪定都能在长达3个月的时间内明显减轻疼痛、残疾和镇痛剂用量。到6个月时,与对照组和右美托咪定组相比,镁组的疼痛评分和MODI明显改善,布洛芬的用量也有所减少:结论:在6个月的观察期内,镁可明显减轻疼痛强度、残疾程度和镇痛剂用量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信